The Audited Finanacial Results (Standalone and Consolidated ) of the Company for Last Quarter and Year Ended March 31, 2025 and Audited Annual Accounts of the Company for the quarter and ....

Revenue declinedNet loss reportedNegative operating cash flowDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.6%Reaction day

₹1.73

prior close

₹1.65

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-4.7% vs market

Trading & Distributors peers, median of 128sector+0.0%-4.6% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Microcap 250 and 4.6 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.6+0.1-4.7+0.0-4.6

Next day

-9.2-0.2-9.1-0.0-9.2

-13.3+0.3-13.6-0.0-13.2

-17.3+0.9-18.2-0.3-17.0

-21.4+0.8-22.2+0.0-21.4

-24.9+2.2-27.0+0.1-24.9

-31.2+3.4-34.6+1.1-32.3

15d

-49.1-0.8-48.3-0.3-48.8

-38.2+2.9-41.1-0.0-38.1

-25.4+0.8-26.3-2.9-22.5

-24.3+0.0-24.3-4.0-20.3

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 128Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Note: The filing headline mentions Supha Pharmachem Ltd, but the document provided is for Remedium Lifecare Limited. The company reported audited standalone and consolidated results for FY25, audited by Taori Sandeep & Associates with an unqualified opinion. On a standalone basis, revenue from operations crashed sharply from Rs 4,07,706.07 lakh in FY24 to Rs 73,345.78 lakh in FY25 (an ~82% fall), while standalone profit after tax dropped from Rs 3,273.02 lakh to Rs 153.20 lakh (an ~95% fall). Q4 FY25 standalone turned into a loss of Rs 264.34 lakh. Consolidated revenue for FY25 stood at Rs 40,525.11 lakh with a PAT of Rs 212.94 lakh, reflecting a newly added subsidiary, Remlife Global PTE LTD (Singapore), which began operations only in Q4 FY25. Total expenses stayed high at Rs 41,166.93 lakh (consolidated), leaving thin margins.

Likely market impact

The steep revenue and profit slide year-on-year, combined with a sharp rise in borrowings (from Rs 32,098 lakh to Rs 1,14,139 lakh at the standalone level), a deeply negative operating cash flow, and a Q4 loss, raises red flags for shareholders. Investors should note the mismatch between the BSE headline (Supha Pharmachem) and the actual filing company (Remedium Lifecare) before acting.